Core Viewpoint - Jinbo Biological is a leading company in the recombinant collagen market, showcasing significant growth in revenue and profit, while emphasizing research and development as the foundation of its business strategy [3][5]. Group 1: Company Overview - Jinbo Biological was listed on the Beijing Stock Exchange in July 2023, recognized as the first A-share company focused on recombinant collagen [3]. - The company specializes in the research, development, production, and sales of high-end implantable medical devices using type A recombinant human collagen as a core material [3]. - Jinbo Biological has been designated as a national-level "specialized, refined, and innovative" small giant enterprise and a key player in the synthetic biology industry chain in Shanxi Province [3]. Group 2: Financial Performance - In 2024, Jinbo Biological reported an annual revenue of 1.443 billion yuan, representing a year-on-year increase of 84.92% [3]. - The net profit attributable to shareholders reached 732 million yuan, with a year-on-year growth of 144.27% [3]. - The growth in revenue is attributed to increases in medical devices, functional skincare products, and raw material sales, driven by sustained R&D investment and market expansion efforts [3]. Group 3: Product Development and Market Strategy - In April 2023, Jinbo Biological developed the world's first injectable recombinant type III human collagen gel using self-assembly and self-crosslinking technology, receiving a Class III medical device registration certificate from the National Medical Products Administration [4]. - The company emphasizes the importance of product effectiveness and safety over the rapid introduction of new products, focusing on quality to establish a strong market presence [5]. - Jinbo Biological aims to expand its international presence, having obtained a D-class medical device registration certificate in Vietnam and patents in multiple countries, including the US and Europe [6]. Group 4: Shareholder Engagement and Dividends - At the annual shareholder meeting, the company announced a cash dividend of 2 yuan per 10 shares and a capital reserve conversion of 3 shares for every 10 shares held, totaling 177 million yuan in cash dividends and 26.55 million shares for distribution [6].
锦波生物股价、市值双双位列北交所第一